ANGIOGENESIS REPRESENTS a complex physiological response of vascular cells to physical or chemical stimuli. In hypoxic or injured tissues, vascular endothelial growth factor (VEGF) is released and initiates a cascade of events including endothelial barrier opening, endothelial cell migration and proliferation, and tube formation (27) . Recent experiments have demonstrated that the production of nitric oxide (NO) comprises a common mechanism underlying VEGF-stimulated morphological and functional changes in endothelial cells (1, 9, 11, 21, 22, 27) . Our previous study in isolated and perfused coronary venules showed that the NO synthase (NOS) inhibitor N G -monomethyl-L-arginine (L-NMMA) prevented the increases in albumin permeability induced by VEGF (29) . Although NO seems to be a critical signaling molecule in the mediation of different cellular responses to the growth factor, the sequence of events that occurs upstream from NO production has not been elucidated. Within this context, it remains unclear whether the intracellular molecules that have long been known to participate in the inflammatory hyperpermeability response (7, 12, 16, 17, 32) , such as phospholipase C (PLC), endothelial cytosolic Ca 2ϩ ([Ca 2ϩ ] i ), and protein kinase C (PKC), are located in the postreceptor signaling pathway of VEGF.
VEGF binds to two different receptor tyrosine kinases, designated Flt-1 and Flk-1/KDR (27) . Although information about Flt-1 is limited, VEGF stimulation of KDR is known to result in phosphorylation of the Src family of protein kinases and the ␥-isoform of phospholipase C (PLC-␥) (10, 15) . KDR transduction has been implicated in the development of endothelial actin reorganization, membrane ruffling, and chemotactic contraction (28) . These morphological changes are often observed in endothelial monolayers undergoing barrier changes in response to inflammatory mediators, implying that KDR-triggered intracellular cascade may be involved in the permeability response to VEGF.
In this study, we hypothesized that VEGF binding to the KDR receptor phosphorylated PLC-␥, which subsequently elevated the intracellular Ca 2ϩ as well as upregulated PKC, leading to NOS activation and NO production. We measured the endothelial permeability to albumin and the [Ca 2ϩ ] i response to VEGF in intact perfused coronary venules. Moreover, immunoprecipitation followed by Western blot analysis was performed using cultured vascular endothelial cells to verify the phosphorylation status of the signaling molecules. The results support a KDR-PLC-Ca 2ϩ /PKC-ecNOS cascade in the venular hyperpermeability reaction elicited by VEGF.
MATERIALS AND METHODS
Materials. An albumin-physiological salt solution (APSS) was used as a bathing solution while the microvessels were being dissected. It contained the following (in mM): 145.0 NaCl, 4.7 KCl, 2.0 CaCl 2 , 1.17 MgSO 4 , 1.2 NaH 2 PO 4 , 5.0 glucose, 2.0 pyruvate, 0.02 EDTA, and 3.0 MOPS buffer. After 1% bovine serum albumin was added, the solution was buffered to a pH of 7.40 at 4°C and then filtered through a Millex-PF 0.22-µm filter unit (Millipore, Bedford, MA). The APSS used to perfuse the vessels during permeability measurements had the same composition as mentioned above but was buffered to a pH of 7.40 at 37°C. The chemicals used to make the perfusate, including FITC-albumin, were pur-chased from Sigma (St. Louis, MO). Bovine serum albumin was obtained from United States Biochemical (Cleveland, OH). Cell culture supplies including the culture media DMEM and fetal bovine serum were from GIBCO (Gaithersburg, MD). VEGF was from R & D System (Minneapolis, MN). The PLC inhibitor U-73122 and the PKC inhibitor bisindolylmaleimide (BIM) were ordered from Calbiochem (San Diego, CA). Antibodies including monoclonal anti-PLC-␥, polyclonal antiphosphotyrosine, and polyclonal antiphosphoserine were from Transduction Laboratory (Lexington, KY). Monoclonal antibody against the extracellular domain of the VEGF receptor KDR was from Sigma, and anti-IgG conjugated with horseradish peroxidase was from Jackson ImmunoResearch Laboratory (West Grove, PA). Fura 2 was ordered from Molecular Probes (Eugene, OR).
Isolation and perfusion of coronary venules. Pigs weighing 9-13 kg were anesthetized with pentobarbital sodium (30 mg/kg iv) and heparinized (250 units/kg iv). After a tracheotomy and intubation, the animal was ventilated with room air. A left thoracotomy was performed, and the heart was electrically fibrillated, excised, and placed in 4°C physiological saline. The coronary sinus was cannulated, and 5 ml india ink-gelatin-physiological salt solution were infused to clearly define venular microvessels. This solution was prepared by adding 0.2 ml india ink (Koh-I-Noor, Bloomsbury, NJ) and 0.35 g porcine skin gelatin to 10 ml warm physiological salt solution and filtering through P8 filter paper (Fisher Scientific, Pittsburgh, PA). Information regarding the validation and limitation of the ink-perfusion procedure has been provided in our previous publications (12, 31) . The method for isolating and cannulating coronary venules has also been described in detail in these studies. Briefly, a suitable venule (length 0.8-1.2 mm, diameter 20-60 µm) was dissected from the surrounding myocardium in a dissecting chamber containing APSS at 4°C with the aid of a Zeiss stereo dissecting microscope. The vessel was transferred to a cannulating chamber that was mounted on a Zeiss axiovert microscope. The isolated vessel was cannulated with an inflow and outflow micropipette on each end and secured with 11-0 suture (Alcon, Fort Worth, TX). A third smaller pipette was inserted into the inflow pipette. The vessel was perfused with either APSS through the outer inflow pipette or APSS containing FITC-albumin through the inner inflow pipette. Each cannulating micropipette was connected to a reservoir, and the vessel was perfused at a relatively constant intraluminal pressure and flow rate. The bath solution in the chamber was maintained at 37°C and pH 7.4 throughout the experiments. The image of the vessel was projected onto a Hamamatsu charged coupled device-intensified camera and was displayed on a high-resolution monochromtic video monitor and recorded onto a VHS video recorder. Diameter of the vessel was measured on-line with a video caliper (Microcirculation Research Institute, Texas A & M University, College Station, TX).
Measurement of venular permeability. The permeability of the vessel was measured with a fluorescence ratio technique (13) . With the use of an optical window of a video photometer positioned over the venules and adjacent space on the monitor, the fluorescent intensity from the window was measured and digitized on-line by a Power Macintosh computer. In each measurement, the isolated venule was first perfused with APSS through the outer inflow pipette to establish a baseline intensity. The venular lumen was then rapidly filled with APSS containing FITC-albumin by switching the perfusion to the inner inflow pipette. This produced an initial step increase, followed by a gradual increase, in fluorescence intensity. There was a step decrease of intensity when the fluorescently labeled molecules were washed out of the vessel lumen by switching the perfusion back to the outer inflow pipette. The apparent solute permeability coefficient of albumin (P a ) was calculated using the equation P a ϭ (1/⌬I f )(dI f /dt) o (r/2), where ⌬I f is the initial step increase in fluorescent intensity, (dI f /dt) o is the initial rate of gradual increase in intensity as the fluorescently labeled solutes diffuse out of the vessel into the extravascular space, and r is the venular radius.
In each experiment, the cannulated venule was perfused at a constant perfusion pressure of 20 cmH 2 O. The preparation was equilibrated for 45-60 min after cannulation, and the measurements were conducted at 36-37°C and a pH of 7.35-7.45. In each vessel, a limited number (4-6) of interventions were applied. The preparations were washed three times and allowed to equilibrate for 10-15 min between interventions. In some vessels, the permeability was monitored over 6 h to ensure that the permeability properties of the venules were not significantly altered with time.
Our previous study (29) demonstrated that VEGF increased venular permeability in a time-and dose-dependent fashion: a maximum permeability increase of two to three times normal was observed in 1-5 min with 10 Ϫ10 M VEGF. In this study, to examine the role of KDR receptor, PLC, or PKC in mediation of VEGF-induced hyperpermeability response, the P a was measured in isolated and perfused coronary venules during inhibition of the above factors. In each group, control measurements were taken for the basal permeability and the P a value after topical application of 10 Ϫ10 M VEGF at 2-5 min. Then the vessels were superfused for 10 min with a monoclonal antibody directed against the extracellular domain of the VEGF receptor KDR (1 µg/ml), the selective PLC antagonist U-73122 (10 Ϫ5 M), or the selective PKC inhibitor BIM (10 Ϫ5 M). The permeability response to the same dose of VEGF was again measured in the presence of the inhibitors. In each intervention, the diameter of venules was monitored to ensure that the changes in P a were not due to alterations in vessel diameter.
Measurement of [Ca 2ϩ ] i in isolated venules. Changes in [Ca 2ϩ ] i were measured using a fluorescence ratio technique with the aid of a microscope photometry system (Photon Technology International), which consisted of a PowerFilter high-speed dual-wavelength illuminator, a high-grade quartz fiber-optic bundle, a D-104B single-channel microscope photometer, and a 710 photon-counting photomultiplier tube (PMT). The cell-permeable form of a fluorescent dye, fura 2-AM, was used as the Ca 2ϩ indicator. To load the endothelium with the indicator, the porcine venule was cannulated as described above and perfused for 20 min at a pressure gradient of 20 cmH 2 O through the inner inflow pipette with APSS containing 5 µM fura 2-AM and 0.05% DMSO. After being loaded, the dye remaining in the extracellular space was washed off by switching the perfusion to the outer inflow pipette containing APSS for 20 min. The loading and washing procedures were performed in the dark at room temperature. The cannulated vessel was then aligned on the optical axis of a Zeiss Axiovert microscope that was connected to the PMT equipped with the photometry system. Emission fluorescence at 510 nm during excitation at 340 and 380 nm was detected by the PMT photon-counting system through the measuring window positioned over the venule and recorded with FeliX, computer software associated with the photometer system. In each experiment, the excitation wavelength alternated between 340 and 380 nm at a rate of 650/s, and the fluorescence intensities at both wavelengths were recorded for 10 min in 5-s intervals. Background correction was automatically controlled by the program through subtraction of the background To obtain the absolute concentration of Ca 2ϩ as a function of the 340-to-380 nm fluorescence ratio, the standard calibration experiment was conducted in vitro as previously described (19) . The free acid form of fura 2 was used to construct an in vitro calibration curve in a small bath chamber to which the standard solution with various concentrations of Ca 2ϩ (Molecular Probes) was added. The value of Ca 2ϩ was calculated as [Ca 2ϩ 
where K d is the dissociation constant, R is the 340-to-380 nm ratio measurement, R min is the ratio in the presence of Ca 2ϩ -free solution, R max is the ratio at a saturating level (39.8 µM) of Ca 2ϩ , and ␤ is the ratio of the fluorescence at 380 nm with 0 Ca 2ϩ to the 380 nm fluorescence with 39.8 µM Ca 2ϩ . Values from the in vitro calibration were as follows: K d ϭ 224, R min ϭ 0.17, R max ϭ 1.54, and ␤ ϭ 3.30.
After loading of fura 2 and equilibration, the vessel was subject to topical administration of VEGF at 10 Ϫ10 M, a concentration that was shown to increase venular permeability by two-to threefold. The fluorescence ratio at 340/380 nm was continuously monitored before and 10 min after adding VEGF. At the end of each experiment, bradykinin (10 Ϫ6 M) and ionomycin (10 Ϫ6 M) were added to the suffusion bath, and the [Ca 2ϩ ] i responses were measured as positive controls.
Cell culture and treatment. Human umbilical vein endothelial cells (HUVEC) were ordered from Clonetics (San Diego, CA). Cells were routinely maintained in gelatin-coated dishes containing EGM-2 culture media with 2% fetal bovine serum (Clonetics). Protein assays indicated that confluent HUVEC grown on a 60-mm dish contained proteins at a level of 150-170 µg.
To examine VEGF-induced tyrosine phosphorylation of PLC-␥, cells were incubated with VEGF (10 Ϫ10 M) for 3-5 min. Immunoprecipitation with a monoclonal antibody directed against PLC-␥ was followed by immunoblotting with an antiphosphotyrosine antibody. In separate dishes, cells were first treated with the anti-KDR antibody (1 µg/ml), U-73122 (10 Ϫ5 M), BIM (10 Ϫ5 M), or L-NMMA (10 Ϫ4 M) for 10 min and then subjected to VEGF stimulation. Our previous study (29) showed that L-NMMA, a specific inhibitor of the endothelial constitutive NO synthase (ecNOS), blocked VEGFinduced hyperpermeability in coronary venules. Therefore, we tried to determine in this study whether VEGF activation of ecNOS was associated with phosphorylation of the enzyme and, if so, whether PLC and PKC were involved in this process. The effect of VEGF on tyrosine or serine phosphorylation of ecNOS was measured during inhibition of PLC and PKC. To inhibit the enzymes, cells were first incubated for 10 min with either U-73122 (10 Ϫ5 M) or BIM (10 Ϫ5 M). Then VEGF (10 Ϫ10 M) was topically added for 5 min followed by quick lysis of the cells.
Immunoprecipitation and Western blot analysis. After the above treatment, confluent cell monolayers in 60-mm dishes were lysed by incubation for 20 min in 1 ml of ice-cold lysis buffer (20 mM Tris · HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 0.15 units/ml aprotinin, 10 µg/ml leupeptin, 10 µg/ml pepstatin A, 1 mM sodium orthovanadate, and 10% glycerol). The lysate was clarified by centrifugation at 14,000 g for 10 min at 4°C. For immunoprecipitation, the lysate was incubated overnight at 4°C with monoclonal antibodies directed against specific proteins, such as anti-PLC-␥ and anti-ecNOS. The extract was then incubated with protein G plus Sepharose 4B (Zymed, San Francisco, CA) for 2 h at 4°C. The immunocomplex was collected by centrifugation at 15,000 g for 10 s and washed three times with cold immunoprecipitation buffer containing 0.1% Triton X-100 and once with 10 mM Tris · HCl at pH 7.4.
Proteins were fractionated by SDS-PAGE on precast 4-12% gradient mini-gels and transferred to nitrocellulose sheets for immunoblotting. To examine phosphorylation, the blots were further incubated for 1 h with a polyclonal antiphosphotyrosine or antiphosphoserine antibody, followed by incubation with a secondary antibody conjugated to horseradish peroxidase. Immunoreactive bands were detected by enhanced chemiluminescence. Images of the bands were scanned by reflectance scanning densitometry, and the intensity of the bands was quantified using NIH Image software. The concentration of protein in cell lysates was determined with Bradford's method using the Bio-Rad protein assay reagent. To ensure that changes in phosphoprotein content were not attributed to the difference in protein content, immunoprecipitated proteins were incubated in parallel with antibodies directed against the same specific proteins as controls.
Data analysis. In the intact vessel studies, P a was measured two to three times for each venule at each experimental intervention, and the values were averaged. For all experiments, n is given as the number of vessels studied, with each vessel representing a separate animal. For each experimental condition, the values of P a from different venules were averaged, normalized to the control values obtained before drug treatments, and reported as percent control in means Ϯ SE. ANOVA was used to evaluate the significance of intergroup differences. A value of P Ͻ 0.05 was considered significant for the comparisons.
RESULTS

VEGF-induced permeability changes in venules.
In control venules ranging from 20 to 60 µm in diameter (n ϭ 6), VEGF (10 Ϫ10 M) significantly increased P a from the basal value of 3.6 Ϯ 0.7 ϫ 10 Ϫ6 to 7.5 Ϯ 0.9 ϫ 10 Ϫ6 cm/s, which was 211.8 Ϯ 14.3% of the basal permeability (Fig. 1) . Blockage of the VEGF receptor KDR or inhibition of the intracellular signaling molecules PLC and PKC abolished the hyperpermeability effect of VEGF. As shown in Fig. 1 , in venules treated with the KDR receptor antibody at 1 µg/ml (n ϭ 9), VEGF (10 Ϫ10 M) did not significantly increase P a ; P a values were 2.7 Ϯ 0.2 ϫ 10 Ϫ6 cm/s before VEGF and 3.1 Ϯ 0.5 ϫ 10 Ϫ6 cm/s after VEGF. Moreover, the venules treated with the selective PLC antagonist U-73122 at 10 Ϫ5 M displayed no hyperpermeability response to VEGF as indicated by a P a value of 2.3 Ϯ 0.3 ϫ 10 Ϫ6 cm/s before and 2.3 Ϯ 0.4 ϫ 10 Ϫ6 cm/s after VEGF (n ϭ 7). Similarly, administration of VEGF did not cause significant increases in venular permeability in the presence of the highly selective PKC inhibitor BIM at 10 Ϫ5 M (P a was 3.1 Ϯ 0.3 ϫ 10 Ϫ6 cm/s before VEGF vs. 3.4 Ϯ 0.3 ϫ 10 Ϫ6 cm/s after VEGF, n ϭ 7) (Fig. 1) . The results indicated that KDR, PLC, and PKC are involved in the mechanism underlying VEGF's effect on venular permeability.
VEGF-elicited Ca 2ϩ response in venules.
The change in the endothelial [Ca 2ϩ ] i in response to topical application of VEGF (10 Ϫ12 to 10 Ϫ9 M) was measured in intact isolated coronary venules. In 12 vessels studied, all of them responded to bradykinin (10 Ϫ6 M, Fig. 2A ) and ionomycin (10 Ϫ6 M, Fig. 2B ) with typical kinetics. However, an increase in [Ca 2ϩ ] i was observed in only four vessels with VEGF at the dose of 10 Ϫ10 M (Fig. 2,  C-F) .
VEGF-stimulated phosphorylation of PLC and ec-NOS. Western blot analyses showed an increase in the phosphotyrosine content of PLC-␥ at 3 and 5 min after administration of 10 Ϫ10 M VEGF (Fig. 3, top) . This effect was not observed in cells treated with the selective PLC inhibitor U-73122 (Fig. 3, middle and bottom) , indicating the specificity of the inhibitor. Treatment of the cells with the anti-KDR antibodies before VEGF stimulation blocked the hyperphosphorylation of PLC-␥, but inhibition of PKC with BIM or blockage of ecNOS with L-NMMA did not significantly reduce the phosphorylation of PLC to VEGF (Fig. 3, middle) . The treat- (Fig. 3, bottom) . The data suggest that KDR served as a tyrosine kinase receptor to trigger PLC-␥ tyrosine phosphorylation, whereas PKC and ecNOS are downstream from PLC activation. Furthermore, the same dose of VEGF was found to cause no changes in tyrosine phosphorylation but an increase in serine phosphorylation of ecNOS (Fig. 4) . The hyperphosphorylation of serine in ecNOS was greatly attenuated by treating the cells with either U-73122 or BIM, suggesting that the activation of PLC and PKC occurred before ecNOS phosphorylation upon VEGF stimulation.
DISCUSSION
We previously reported that VEGF induced an increase in venular permeability through the production of NO. This study further examined the role of the VEGF receptor KDR and several postreceptor signaling molecules in the transduction of microvascular permeability response to VEGF. There are three new findings: 1) the effect of VEGF on endothelial barrier function is triggered by VEGF binding of KDR receptor and subsequent activation of PLC; 2) PKC is a major intermediate between activated PLC and ecNOS, although [Ca 2ϩ ] i may also be involved; and 3) VEGF activates PLC and ecNOS by upregulating PLC-␥ tyrosine phosphorylation and ecNOS serine phosphorylation. From our current and previous findings (28), we suggest that VEGF increases microvascular permeability via a signaling cascade initiated by KDR activation of PLC, mediated by PKC upregulation and/or [Ca 2ϩ ] i elevation, and culminated with ecNOS-catalyzed NO production.
The central role of NO in mediating the angiogenic action of VEGF has recently been documented. NO is considered to be a chemoattractant and mitogen to bovine coronary venular endothelial cells (34) . In HUVEC, VEGF promotes cell growth and formation of networklike structure through a NO-dependent mechanism in which long-term exposure to VEGF increases ecNOS protein level and short-term exposure stimulates the release of NO (11, 21) . Direct measurements of NO production confirm that VEGF produces a doseand time-dependent rise in NO concentration from various vascular segments or cultured endothelial cells (1, 11, 33) . Consistent with the mitogenic action, the VEGF effect on microvascular permeability is linked to NO production, for VEGF-induced protein leakage can (29) and in vivo Mile's assays (9) . Although the NO cascade seems to serve as a common pathway leading to VEGF-stimulated endothelial proliferation and hyperpermeability, information is limited regarding the signal transduction from cell membrane to cytosol before NO production.
Chemical regulation of endothelial barrier function is mediated by soluble agonist occupancy of PLC-associated receptors (16, 24, 32) . Two typical intermediates that are downstream of activated PLC are endothelial cytosolic Ca 2ϩ and PKC (12, 16) . For histamine-type inflammatory agonists, PLC hydrolysis of phosphotidylinositol bisphosphate and subsequent Ca 2ϩ mobilization are the primary triggers of transendothelial flux of macromolecules (16, 24, 27) . The relationship between [Ca 2ϩ ] i and NO production is well established based on the fact that elevated Ca 2ϩ is a potent stimulator of the constitutive NO synthase (25) . On the other hand, a group of agonists, such as phorbol esters, bradykinin, and platelet-activating factor, alters endothelial barrier function via a PKC-dependent mechanism (12, 14, 17, 20) . The underlying enzymatic reaction involves PLC-catalyzed diacylglycerol formation and subsequent PKC activation (16) . Recent evidence indicates a potential linkage between PKC and NOS in that PKC can activate NOS to produce NO in different types of cells (18, 26) .
In this study, we tested whether the KDR-PLC-Ca 2ϩ / PKC-ecNOS cascade contributed to the venular permeability response to VEGF, a unique hyperpermeability factor that is well known for its tyrosine kinase receptor activity (27) . Our finding that the anti-KDR antibody blocked VEGF's effects on venular permeability and PLC-␥ tyrosine phosphorylation emphasizes the importance of KDR receptor. In support of the KDR hypothesis, experiments show that KDR-expressing cells display striking changes in cell morphology, actin reorganization, membrane ruffling, chemotaxis, and mitogenicity upon VEGF stimulation, whereas Flt-1-expressing cells lack such responses (28) . Adding to this is that the K d value of Flt-1 is in the picomolar range, whereas KDR has a K d value at the subnanomolar level (5); the latter is consistent with the permeability dose response observed in our studies. Evidence is accumulating that VEGF binding to its tyrosine kinase receptor KDR results in tyrosine phosphorylation of various signaling proteins (10, 15, 22) . Among the effector proteins, PLC-␥ has been identified as important for its ability to propagate the signal to the downstream events characterized by Ca 2ϩ mobilization and PKC upregulation. In this regard, PLC-␥ is activated through tyrosine phosphorylation by VEGF (27) , whereas KDR may serve as the primary kinase receptor that phosphorylates PLC-␥ directly or indirectly through other SH2-containing molecules (10, 27) .
The intracellular Ca 2ϩ study, in which only one-third of venules responded to VEGF with Ca 2ϩ spikes, argues against the primary or sole role of Ca 2ϩ in VEGF action. Previous work on cultured endothelial cells reported that VEGF induced a transient elevation of [Ca 2ϩ ] i , which was interpreted as a PLC-stimulated internal Ca 2ϩ release followed by a predominant external Ca 2ϩ influx (4, 6) . However, a recent study on intact perfused frog mesenteric microvessels (3) demonstrated that in eight vessels with typical Ca 2ϩ responses to ionomycin, VEGF produced a significant increase in four, a small increase in two, and no response in [Ca 2ϩ ] i in two vessels. Apparently, the Ca 2ϩ kinetics vary in different preparations under different experimental conditions. Compared with the above studies, the Ca 2ϩ response to VEGF in coronary venules occurred in a smaller fraction of vessels. Taking the data from the current observation together with our previous results (29) , the majority (Ͼ90%) of venules responded to the same concentration of VEGF with an increased permeability, but only one-third exhibited a Ca 2ϩ transient. Thus the elevation of [Ca 2ϩ ] i does not seem to be a necessary step in the permeability response to VEGF. However, the presence of Ca 2ϩ is required for the maintenance of basal barrier function and NOS activity (7, 26) .
In contrast to Ca 2ϩ , PKC may play a role in mediation of VEGF's effect on vascular permeability, as indicated by the efficient inhibition of VEGF-induced protein leakage by a selective PKC inhibitor. Although our current technique did not allow direct quantification of PKC activity in intact perfused microvessels, the phar- http://ajpheart.physiology.org/ macological approaches combined with the in vitro Western blot analysis provided evidence for the role of PKC as an integral component in transducing the VEGF signal from PLC to ecNOS. Indeed, other studies on bovine aortic endothelial cells (30) showed that VEGF induced a concentration-and time-dependent increase in PKC activity, and the effect was preceded by the activation of PLC-␥. Within this context, a parallel increase in PLC-␥ tyrosine phosphorylation, inositol phosphate production, and diacylglycerol formation was detected in VEGF-stimulated cells (30) . In retina, administration of a PKC-selective inhibitor did not affect histamine-induced but inhibited at 95% level VEGF-induced microvascular leakage (2) . With regard to the signals downstream of PKC, a potential effector protein is ecNOS. As a serine kinase, PKC may induce serine phosphorylation of ecNOS and subsequent NO production, which in turn leads to venular hyperpermeability. This hypothesis is supported by a correlation of the current finding that inhibition of PKC attenuated the VEGF-stimulated serine phosphorylation of ecNOS with our previous data that L-NMMA greatly attenuated the permeability response to PKC activators (12) . Adding to this is a report of in vivo measurements of microvascular permeability in which the NOS inhibitor antagonized PKC-regulated macromolecular transport (23) . More recently, serine phosphorylation of ecNOS was detected in the hamster cheek pouch treated with platelet-activating factor, a PKC-dependent hyperpermeability mediator (8, 14) .
In summary, this study reports that VEGF stimulation of endothelial cells upregulates tyrosine phosphorylation of PLC-␥ and serine phosphorylation of ecNOS through a KDR receptor-triggered pathway. Consistently, the effect of VEGF on venular permeability is blocked during inhibition of KDR, PLC, PKC, or ec-NOS, suggesting that the KDR-PLC-Ca 2ϩ /PKC-ecNOS cascade is involved in signaling mechanisms underlying the microvascular hyperpermeability response to VEGF.
